**UNITED STATES**
**SECURITIES AND EXCHANGE COMMISSION**
**Washington, DC 20549**

# FORM 8-K

**CURRENT REPORT**
**Pursuant to Section 13 or 15(d) of the**
**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): September 1, 2015**

# OPKO Health, Inc.

(Exact Name of Registrant as Specified in Charter)

| **Delaware** | **001-33528** | **75-2402409** |
|---|---|---|
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |

**4400 Biscayne Blvd**
**Miami, Florida 33137**
(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (305) 575-4100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

## ITEM 7.01. Regulation FD Disclosure.

On September 1, 2015, members of management for OPKO Health, Inc. (the "Company") attended the Barrington Research Fall Investment Conference in Chicago and participated in one on one meetings with investors. A copy of the Company's slides used in the meetings is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The presentation slides are also available on the OPKO website at www.opko.com under Investor Relations. The information contained on OPKO's website shall not be deemed part of this report.

The information contained in Item 7.01 to this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing by the Company under the Act, unless expressly stated otherwise.

## ITEM 9.01. Financial Statements and Exhibits

*(d) Exhibits*

| Exhibit Number | Description |
|---|---|
| 99.1 | OPKO Health, Inc. Presentation Materials. |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OPKO Health, Inc.

By /s/ Adam Logal

Name: Adam Logal
Title: Senior Vice President, Chief Financial Officer

Date September 1, 2015

## EXHIBIT INDEX

| Exhibit No. | Description |
|---|---|
| 99.1 | OPKO Health, Inc. Presentation Materials |

Exhibit 99.1

# September 2015

# Cautionary Statement

This presentation contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," "potential" and other words of similar meaning, including statements regarding our estimated revenues and financial projections, our ability to achieve high levels of growth, the potential for our products under development, the potential of the 4Kscore® to reduce prostate biopsies and predict the risk of aggressive prostate cancer, our ability to develop, test and launch new products, the expected timing of the clinical studies and regulatory submissions relating to our products under development, the outcome of our clinical trials and validation studies and that such outcomes will support commercialization, the expected market penetration and size of the market for our products under development, including without limitation, Rolapitant™, Rayaldee™ (CTAP-101), hGH-CTP, the 4Kscore, Factor VIIa-CTP, oxyntomodulin, and our point-of-care diagnostic product for PSA, the potential benefits of our products under development, including whether the 4Kscore will improve selection of candidates for prostate biopsy, predict the risk of distant metastases, and result in 40-56% cost savings, the expected PMA submission date for PSA, expected per patient savings, whether MOD-6031 will provide superior long-term therapy for obesity and Type II diabetes patients, our ability to successfully commercialize our product candidates such as Rolapitant, the 4Kscore, Rayaldee (CTAP-101), hGH-CTP, Factor VIIa-CTP, and oxyntomodulin, as well as products for other markets, whether we will be able to develop Rayaldee (CTAP-101) for additional indications and whether Rayaldee (CTAP-101) will take significant market share in Stage 3 and 4 CKD patients with SHPT, whether Rayaldee (CTAP-101) will raise serum total 25-hydroxyvitamin D (25D) more effectively than any over-the-counter (OTC) or prescription (Rx) product currently marketed without the risk of hypercalcemia, whether we can reach more than half of the CKD population with a small sales force, our ability to establish a sales and marketing and clinical support infrastructure for Rayaldee and the timeline for doing so, the expected PDUFA date and launch date for Rayaldee, expectations regarding patent coverage, the expected timing for commencing, completing and obtaining results for our clinical trials, the timing for release of trial data and seeking and obtaining FDA and European regulatory approvals as well as reimbursement coverage, and the timing of commercial launch of our product candidates, expectations about near term profitability, that EirGen will manufacture our current and future products resulting in higher margins, that Bio-Reference's vast array of genetics and genomics data will benefit OPKO, as well as other non-historical statements. These forward-looking statements are only predictions and reflect our views as of the date they were made, and we undertake no obligation to update such statements. Such statements are subject to many risks and uncertainties that could cause our activities or actual results to differ materially from the activities and results anticipated in forward-looking statements, including integration challenges with Bio-Reference, risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments, the success of our collaboration with Pfizer, general market factors, competitive product development, product availability, federal and state regulations and legislation, and integration issues arising from the transactions, delays associated with development of novel technologies, unexpected difficulties and delays in validating and testing product candidates, the regulatory process for new products and indications, manufacturing issues that may arise, the cost of funding lengthy research programs, the need for and availability of additional capital, the possibility of infringing a third party's patents or other intellectual property rights, the uncertainty of obtaining patents covering our products and processes and in successfully enforcing them against third parties, and the possibility of litigation, among other factors, including all of the risks identified under the heading Risk Factors in our Annual Report on Form 10-K and other filings with the Securities and Exchange Commission.

# What's New?

- Completed Acquisition of Bio-Reference Laboratories August 20, 2015
- Acquired EirGen Pharma, a Growing, Profitable Specialty Pharmaceutical Developer and Manufacturer
- Rayaldee™ PDUFA Date – March 29, 2016
- 4Kscore® Included in NCCN Guidelines - CPT Code Became Active on July 1, 2015 – Company Began Billing Insurance for the Test
- Enrolling Patients for Long-Acting Factor VIIa-CTP Phase IIa Clinical Trial to Commence Q4

# A High-Growth Diversified Medical Products Company

| | |
|---|---|
| **Diagnostics** | - Bio Reference Laboratories – a unique clinical lab<br>- 4Kscore® blood test for aggressive prostate cancer risk<br>- Claros 1® immunoassay system for rapid, lab quality in-office testing |
| **Pharmaceuticals** | - Vitamin D therapeutics for SHPT<br>- Platform technology to make peptides and proteins long-acting for treatment of growth hormone deficiency, hemophilia, obesity, etc.<br>- Calcium-free, magnesium-based phosphate binder |
| **International Markets** | - Established businesses in:<br>▪ United States ▪ Spain ▪ Israel ▪ Ireland<br>▪ Chile ▪ Uruguay ▪ Mexico |
| **Opportunistic Investments** | - Innovative technologies:<br>▪ Antibodies ▪ Cardiovascular devices<br>▪ Anti-virals ▪ RNAi |

# Acquired EirGen Pharma, Ltd.

- Developer of High Potency Specialty Pharmaceutical Products
  - Growing, profitable and cash flow positive
  - Cancer chemotherapy and other niche, high potency drugs require special expertise and infrastructure - significant barriers to entry
- Rich Pipeline of Products
  - 10 product applications filed with the FDA, 3 approved, 4 filings in Europe, all approved, and 5 in Japan, 4 approved
  - Over 27 additional drugs in development
  - Opportunities to commercialize products through OPKO operations world-wide
    - Product registrations by OPKO Chile with others expected
- State-of-the-Art High Containment R&D and Manufacturing Facility
  - Approved by the FDA, EMEA (European Health Authorities) and PMDA (Japan)
  - Potential to manufacture OPKO's current and future products with resulting higher gross margins
- Co-Founded by Former IVAX Pharmaceuticals Executives

OPKO

# Bio-Reference is a Unique Clinical Lab Asset – Acquisition closed August 20, 2015

1. **Demonstrated** strong, consistent organic growth - 21 years of ~20% compound annual revenue growth
2. **Created and expanded** franchises in multiple specialty markets including oncology, women's health and genetics in lab testing and healthcare provider communities
3. **Commercialized** innovations in clinical testing and informatics: GenPap, PanEthnic Carrier Screen, OnkoSight, Genome DX, Next-Gen Clinical Testing, Whole Exome Sequencing, PsiMedica and CareEvolve
4. **Positioned** itself securely on the cutting edge of Genetic Medicine through GeneDx
5. **Built** a strong corporate culture with an outstanding industry leading medical and scientific team with long company tenure and strong commitment to BRLI

# 1 Transaction Rationale: Near-term

OPKO + BioReference Laboratories

**Leverage BRLI's channels to accelerate the adoption of OPKO's diagnostic products**

- Extensive phlebotomy draw stations offer synergistic opportunity for efficient commercialization of 4Kscore test for high-grade prostate cancer
  - ~175 BRLI patient service centers located throughout the US for collection of patient specimens
- Leverage the national marketing, sales, and distribution resources of BRLIto enhance sales of OPKO's diagnostic platforms
  - ~420 sales and marketing personnel
  - ~5,000 people working together to support the needs of clients and patients
- Near-term profitability supports the development of existing pharmaceutical pipeline

# 2 Transaction Rationale: Longer-term

OPKO + BioReference Laboratories

**Utilization of genomic data for personalized therapy**

- BRLI's vast array of genetics and genomics data should benefit OPKO in its drug discovery and clinical trial programs
  - GeneDx was the first commercial laboratory to offer next generation sequencing for panels
  - Offers 620+ single gene tests along with numerous panel-based tests, including inherited cancers, to over 250 providers in 25 countries, many unique to GeneDx
  - Performs more whole exome testing than any other commercial laboratory in the world
- OPKO's research capabilities deepen the insights into the genetic information and further strengthen the GeneDx offering

# Bio-Reference has Developed Capability in Specialty Areas




**Shared Resources**: infrastructure and senior management, scientific expertise and clinical acumen

**Unique Specialty Capabilities**: market (product) specific expertise, specialized clinical connection and applications and focused product managers and marketing materials

# The 4Kscore Test as a Minimally Invasive Alternative to Prostate Biopsy

- Clinical utility is based on three decades of clinical biomarker research and over 20,000 men tested in Europe and the US
- Identifies the actual risk of aggressive prostate cancer for the individual patient with:
  - High grade prostate cancer pathology
  - Poor prostate cancer clinical outcomes within 20 years
- Has high sensitivity and high negative predictive value for aggressive prostate cancer
- 40–56% cost savings to potentially avoid unnecessary MRI and prostate biopsies
- **The only blood test that accurately identifies risk for aggressive prostate cancer**

**1 million U.S. biopsy patients per year; over 2 million patients world-wide**

# What is the 4Kscore Test?

**Components**

4 kallikrein levels:

OPKO { Total PSA, Free PSA, Intact PSA, hK2

+

Age, DRE, and prior biopsy status

**OPKO ALGORITHM**



**Results**

% risk of having aggressive prostate cancer for an individual patient

OPKO


700,000
PSA Screenings
140,000
Abnormal PSA or DRE
100,000
Standard TRUS or
mp MRI-Guided Biopsy
4,000 Serious
Infections
Biopsy Result
55,000
25,000
20,000
Negative Biopsy
Histopathology
Gleason score 6
Histopathology
OncotypeDx
or Prolaris
Gleason score ≥ 7
Histopathology
7,500
17,500
Monitor w_ PSA
or PCA3, ConfirmMDx
Active
Surveillance
Primary Treatment
Surgery / Radiation
Primary Treatment
Surgery / Radiation
12,000 with Confirmed
Indolent Disease


700,000
PSA Screenings
100,000
Prostate Biopsy Patients
4Kscore® Test
36% Biopsy
Reduction
$78M Savings
Standard TRUS or
mp MRI-Guided Biopsy
51% Reduction$22
M Savings
29% Reduction$16
M Savings
Biopsy Result
Negative Biopsy
Histopathology
Gleason score 6
Histopathology
OncotypeDx
or Prolaris
Gleason score ≥ 7
Histopathology
29% Reduction$146
M Savings
Monitor w_ PSA
if abnormal, 4Kscore
Active
Surveillance
Primary Treatment
Surgery / Radiation
Primary Treatment
Surgery / Radiation
$143 M net savings / $1,400 per patient

# The 4Kscore Test Predicts Metastases Within 20 years[1]




**16%**

4Kscore Test > 7.5%

4Kscore Test ≤ 7.5%

**< 2%**

[1] Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case–Control Study European Urology (in press)

OPKO

# 4Kscore Commercial Update

- 4Kscore ProtecT study published – over 6,000 subjects
  - Total now 22,000 subjects studied with 4K panel
- Over 1,000 US urologists have used the 4Kscore test in routine practice
- American Urological Society Meeting in New Orleans May, 2015 – six podium or poster presentations
- NCCN Early Detection Guidelines Published July 2015
- Next milestone:
  - Medicare and private insurance coverage for test: 2015/16

# Claros ®1: Rapid Testing in the Physician Office



# Claros 1 Platform Addresses Large Testing Markets

- PSA
  - US test volume: 30 million tests, $750 M
  - Intended use to focus on detection claim
  - Modular PMA filing with FDA in 2016
- Other Test Menus in Development
  - Aligned with BRL specialty sales focus
- Sectors
  - Oncology
  - Women's Health
  - Health and Wellness

# OPKO Pharmaceuticals–Advanced, Deep Pipeline

| Product | Indication | Preclinical | Phase 1 | Phase 2 | Phase 3 | Milestone | Market Size |
|---|---|---|---|---|---|---|---|
| **Rayaldee™ (CTAP101)** | SHPT (CKD Stage 3-4 Patients) | | | | | PDUFA date March 29, 2016 | $12.0 BN |
| **hGH-CTP** | hGH deficiency | | Collaboration with Pfizer | | | | $3.0 BN |
| **Alpharen™ (Fermagate)** | Hyperphosphatemia (CKD Stage 5 Patients) | | | | | | $1.2 BN |
| **Rolapitant** | CINV | | Outlicensed to TESARO | | | PDUFA date September 5, 2015 | $1.5 BN |
| **CTAP201** | Mild to moderate SHPT (CKD Stage 5 Patients) | | | | | | $1.1 BN |
| **Factor VIIa-CTP** | Hemophilia | | | | | Phase 2a trial expected in 4Q 2015 | $1.7 BN |
| **Oxyntomodulin** | Diabetes, Obesity | | | | | Phase I trial targeted for Q1 2016 | $15 BN |
| **AntagoNAT Platform** | Cancer, CV, metabolic and orphan disease | | | | | | $1.0 BN |
| **CYP24 Inhibitors** | SHPT, CKD, cancer | | | | | | $1.0 BN |

# Rayaldee – A Late-Stage Investigational Drug

## Product Overview

- Modified-release (MR) oral formulation of $25D_3$* addresses significant unmet market need
- Safe and effective treatment for elevated PTH (SHPT) associated with low 25D levels in Stages 3–4 CKD
- Achieves more reliable increases in serum 25D and reductions in plasma PTH than nutritional vitamin D
- Lower risk of side effects compared to active 1,25D ** products
- Preserves protective renal feedback mechanism, reducing upregulation of CYP24 which limits effectiveness of current hormone replacement therapies
- Additional potential for new indications including stage 5 CKD, institutionalized elderly, osteoporosis & cancer

OPKO

* 25-Hydroxyvitamin $D_3$ or Calcifediol
** 1,25-Dihydroxyvitamin $D_3$ or Calcitriol

# Market Opportunity: Chronic Kidney Disease (US)

- The CKD patient population is large and growing as a result of:
  - Obesity
  - Hypertension
  - Diabetes

| Stage | Kidney Function | CKD Prevalence | % of CKD Patients with | | |
|---|---|---|---|---|---|
| | | | Vitamin D Insufficiency ( 25D) | SHPT ( PTH) | Hyperphosphatemia ( Phosphorus) |
| 3 | Moderate impairment | 18.7 Million* | 71% | 40% | 37% |
| 4 | Severe impairment | 1.4 Million* | 83% | 82% | 50% |
| 5 | Failure | 0.5 Million* | 97% | 95% | 70% |

*US Renal Data Service 2013 Annual Data Report
Sources: Levin, A et al., Kidney International 2007; 71: pp.31-38; Gonzalez, E et al. Am J Nephrol 2004;24:503-510; LaClair, R et al. Am J Kidney Dis 2005;45:1026-1033; Tentori, F et al., Clin J Am Soc Nephrol 2015; 10:98-109

# Comparison of Vitamin D Therapies for Stage 3-4 CKD

| | | Effect on Blood Levels of: | | | |
|---|---|---|---|---|---|
| Drug | Active | Type | 25D** | Ca | iPTH |
| Rayaldee | Calcifediol (25-hydroxyvitamin $D_3$) | Rx | ↑ | — | ↓ |
| Vitamin D | Cholecalciferol/Ergocalciferol (vitamin $D_3$/vitamin $D_2$) | OTC | ↑ | — | ↓ |
| Drisdol ™* | Ergocalciferol (vitamin $D_2$) | Rx | ↑ | — | ↓ |
| Rocaltrol ™* | Calcitriol (1a,25-dihydroxyvitamin $D_3$) | Rx | ↓ | ↑ | ↓ |
| Hectorol ™* | Doxercalciferol (1a-hydroxyvitamin $D_2$) | Rx | ↓ | ↑ | ↓ |
| Zemplar ™* | Paricalcitol (19-nor-1a,25-dihydroxyvitamin $D_2$) | Rx | ↓ | ↑ | ↓ |

*And generics
**25-hydroxyvitamin D

# Rayaldee - Commercial Opportunity

**Stage 3 & 4 CKD Treatment for SHPT**




**Rayaldee is expected to take significant market share in Stage 3 and 4 CKD patients suffering from SHPT – a potential $12 billion revenue opportunity**

Source: BioTrends Research Group, Inc. December 2013

# Rayaldee Top-Line Phase 3 Data: Plasma iPTH




OPKO

# Rayaldee Top-Line Phase 3 Data: Serum 25D




OPKO

# Rayaldee Top-Line Phase 3 Data: Serum Ca & P




OPKO

* Significantly different from placebo, $p < 0.05$

# Rayaldee – Steps to Commercialization

- NDA filing (accepted for full FDA review) in late July
- Marketing & sales management team to be hired in Q3-Q4 2015
- PDUFA date: March 29, 2016
- Launch expected within 3 months of PDUFA date
- Initial line extension plans:
  - Additional phase 3 clinical trial(s) planned in stage 5 CKD
  - Initial clinical trial ongoing for new oncology indication
  - Other indications being evaluated

# OPKO Biologics: Extends the Half-Life of Protein Drugs

**Developing biobetter long acting proteins and peptides**

**CTP Technology**

**Reversible Pegylation Technology**

- Significant reduction in injection frequency
- Safety profile comparable to non-modified active therapeutic agents
- Potential expanded prophylactic uses with longer half life agents, in addition to short-term treatment
- Maintain drug bio-activity

# CTP Increases Protein Circulation Time

## CTP – A Natural Chemical Entity Created During Evolution to Enhance Longevity of the Hormone hCG



# Global Collaboration with Pfizer for OPKO's Long-Acting Human Growth Hormone (hGH-CTP)

## Collaboration Terms:

| | |
|---|---|
| **Financial** | – $295 M up-front payment<br>– $275 M for achievement of regulatory based milestones |
| **Development** | – OPKO responsible for funding development program for the key indications:<br>• Adult and Pediatric Growth Hormone Deficiency (GHD)<br>• Pediatric Short for Gestational Age<br>– Pfizer responsible for funding:<br>• Development programs for additional indications<br>• All Post Marketing Studies<br>• All Commercialization Activities |
| **Commercial** | – Initial double digit tiered royalties on sales of Adult GHD<br>– Profit sharing commencing upon launch for Pediatric GHD encompassing combined sales for all indications of OPKO's hGH-CTP and Pfizer's Genotropin<br>– Pfizer Genotropin represents about 25% of the world market with annual revenues exceeding $700 M |

# hGH-CTP Competitive Advantages

- New molecular entity and maintain natural native sequence of GH
- Human growth hormone is used for:
  - Growth hormone deficient children
  - Growth hormone deficient adults
  - SGA, PWS, ISS
- Once-a-week injection (current products require daily injections)
- Final Presentation:
  - The drug product will be a refrigerated, liquid non viscous formulation
  - Injected using a disposable easy to handle pen device with a thin needle and low injection volume
- Pivotal Phase 3 study in growth hormone deficient adults (on-going)
- Phase 2 study in naive growth hormone deficiency pediatric population has been completed
- Orphan drug designation in the US & EU for the treatment of children & adults with GHD

# Daily hGH Market is $3B, Undifferentiated and Growing

## Established and growing




## Fragmented




## Projected market growth

## Competition based on history, service and device innovation

Source: Market Research 2013 & 2014

OPKO

# MOD-5014: Long-acting Factor VIIa for Hemophilia A & B

- $1.7 billion market
  - Growing 7% annually
  - Only 25% of patients are treated
- Current product (NovoSeven®) requires frequent IV doses
  - 3-4 times a day during bleeding episodes
  - 1-2 times a day for prophylactic treatment
- Pharmacological studies in hemophilic mice and dogs FVIIa-CTP demonstrated:
  - Potential for via subcutaneous administration
  - Reduced frequency of injection during on-demand therapy
  - Enable prophylactic treatment while reducing the frequency of injections to 2-3 times a week
- Phase 2a study to Commence Q4
- Orphan drug designation in the US and EU

OPKO

# Oxyntomodulin – Nature's Appetite Control Mechanism




- Natural appetite suppressor
- Oxyntomodulin is a dual GLP-1/Glucagon receptor agonist
- Secreted by the digestive system following food intake and induces satiety in the brain
- Crosses blood-brain barrier to induce satiety
- Increases glucose tolerance in insulin resistance pre-diabetic state associated with obesity

Development challenge: Oxyntomodulin has short half-life which requires multiple daily injections

OPKO solution: MOD-6030, a reversible PEG $_{30}$ formulation which provides 12-fold reduction in dosing frequency

OPKO

# MOD 6031: Meets Unmet Market Need

- MOD-6031 significantly inhibits food intake and reduces body weight by reduction in fat
- MOD-6031 improves glycemic control by inducing glucose dependent insulin secretion (direct mechanism) and by reducing fat (indirect mechanism)
- MOD-6031 improves lipid profile
- MOD-6031 is expected to provide effective long-term therapy for obese and type II diabetes patients
- A battery of comprehensive toxicological studies have been completed confirming the safety of MOD-6031 following a single injection
- Phase 1 study evaluating the safety and pk-pd profile of MOD-6031 in overweight or obese health volunteers is scheduled to be initiated in early Q1 2016

OPKO

# Rolapitant – Potential Near-Term Revenue Driver

- Rolapitant out-licensed to Tesaro in December 2010
  - Payments of up to $121 million
  - Double-digit tiered royalties
- Differentiated cancer supportive care product with $1.5B US Market Opportunity
  - Potent neurokinin-1(NK-1) receptor antagonist for chemotherapy-induced nausea and vomiting (CINV)
  - Opportunity to differentiate on convenience, market access and safety
    - Single dose
    - Lack of CYP 3A4 drug-drug interactions
    - Long acting
    - Oral and IV formulations allow full market access
- PDUFA Date September 5, 2015
  - All three Phase 3 trials (MEC* and HEC**) achieved primary endpoint
  - Primary endpoint: complete response (no emesis and no use of rescue medication)
  - Third Phase 3 trial (HEC) also achieved all secondary endpoints, including:
    - Complete response in acute (0-24 hrs) and overall (0-120 hrs) phase of CINV
    - No significant nausea
  - Successful completion of bioequivalence study for intravenous formulation

OPKO

[1] Moderately emetogenic chemotherapy
[2] Highly emetogenic chemotherapy

# Strategic Investments

***Proprietary Technologies with Significant Upside Potential***

- ARNO Therapeutics, Inc. (OTC: ARNI) (~4% equity interest)
  - Anti-progestin therapy for breast (phase 2) , endometrial and prostate cancers
- Zebra Biologics, Inc. (~27% equity interest)
  - Combinatorial antibody libraries based on function in human cell screens
- OAO Pharmsynthez (MICE: LIFE) (~17% equity interest)
  - Russian developer and marketer of new drugs
- RXi Pharmaceuticals Corporation (NASDAQ: RXII) (~10% equity interest)
  - sRNA to prevent hypertrophic scars (phase 2)
- Cocrystal Pharma, Inc. (OTC: COCP) (~8% equity interest)
  - New anti-virals (Hepatitis C, flu) superior molecules for combination therapy (pan-genotypic)
- Sevion Therapeutics, Inc. (OTC: SVON) (~ 4% equity interest*)
  - Antibodies against difficult targets (e.g., G protein-coupled receptor, ion channels)
- Neovasc, Inc. (NASDAQ: NVCN) (~ 5% equity interest)
  - Cardiology devices (transcutaneous mitral valve)
- ChromaDex, Inc. (OTC: CDXC) (~ 2% equity interest)
  - New nutritional supplement APIs
- MabVax Therapeutics Holdings, Inc. (OTC: MBVX) (~7% equity interest)
  - Cancer Immunotherapy Company
- SciVac Therapeutics, Inc (TSX: VAC) (~25% equity interest)
  - Third-generation hepatitis B vaccine